FDA And FTC Continue To Collaborate On Biosimilar Competition
Agencies Working Together To Address Anticompetitive Market And Combat Misinformation
The FDA and FTC have been working on improving information exchange about activities which could undermine biosimilar competition, as well as addressing misinformation about factors such as interchangeability.
